ZIM
RARE icon

Zacks Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Zacks Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,026
Closed -$1.04M – 603
2019
Q1 		$1.04M Hold
15,026
– – 0.02% 390
2018
Q4 		$653K Sell
15,026
-3,531
-19% -$193K 0.02% 411
2018
Q3 		$1.42M Buy
+18,557
New +$1.51M 0.03% 338

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Zacks Investment Management's RARE Position: Q2 2019 in Review

Zacks Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 15,026 shares — an estimated $1.04M sold.

Zacks Investment Management first reported a position in RARE in Q3 2018 and held it in 3 quarters. The position peaked at $1.42M in Q3 2018. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

  • Zacks Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Zacks Investment Management sold 15,026 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $1.04M.
  • Zacks Investment Management first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 3 quarters.
  • Zacks Investment Management's Ultragenyx Pharmaceutical position peaked at $1.42M in Q3 2018.
  • 170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on Zacks Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.